French drugmaker Sanofi is poised to commit between 1.3 billion euros and 1.5 billion euros ($1.4 billion – $1.6 billion) to enhancing its insulin production site in Frankfurt, Germany. The site in Frankfurt’s Hoechst district is known for producing the company’s insulin brand, Lantus. Also Read: Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M. This move comes after initial plans to shift Lantus production to France were reconsidered. The decision ...